Frequently found in NSCLC, the gene TP53 mutations are associated with the resistance to chemotherapy and shorter overall survival, although, due to the abundance of different mutations, it is difficult to find prospective targets for therapy. Here, TP53 is linked to non-small cell lung carcinoma.